Navigation Links
Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
Date:7/29/2010

its future diagnostic products; (4) uncertainty of market acceptance of its OVA1™ diagnostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.   In addition, any financial information presented in this press release is unaudited and subject to adjustment following Vermillion's internal review and quarterly processes as well as annual audit.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vermillion Announces Relocation of Corporate Offices to Austin, Texas
2. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
3. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
4. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
5. Vermillion Announces the Reappointment of Officers and Confirmation of Director
6. Vermillion Announces $43.05 Million Private Placement of Common Stock
7. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
8. Vermillion Files Plan of Reorganization
9. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
10. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
11. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
(Date:9/30/2014)... , Sept. 30, 2014  HealthLoop® released an ... with HealthKit in iOS 8 and allows people to ... The app harnesses native iOS technologies to enhance the ... a robust connection with their doctors between visits. ... and the data they collect is exciting," says HealthLoop ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 ... oncology tissue diagnostics market, Frost & Sullivan recognizes ... the Roche Group, with the 2014 North American ... Adherence to strict quality practices along with a ... made Ventana a global leader in tissue-based cancer ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... and Drug Administration today issued new guidance that advises ... to administer influenza vaccinations. Based on this advice, The ... use of such clinical devices at all pharmacies and ... family of pharmacies and The Little Clinic locations will ...
... 21, 2011 Boca Pharmacal, Inc., today announced that it ... Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and ... and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, ... in the treatment of peptic ulcers. "We,re up ...
Cached Medicine Technology:Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets 2
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... Elevate , the latest product from ... and out of the gym by providing natural ingredients that ... of Shane Michaels, prompting an investigative review. , “When ... most people simply just don’t have the ability to perform ... work, getting the motivation to finish a project, or even ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... Dr. Karl R.O.S. Johnson, DC, has ... of care that is dramatically improving the health and ... Neurology & Nutrition—applies a proprietary, multi-dimensional approach that goes ... sources of inflammation, neurology of the joint and neurology ... the brain to the spine, to the legs, knees ...
(Date:9/30/2014)... 2014) Levothyroxine is considered the gold standard therapy ... review of therapies for the condition including combining ... assessment, say a team of investigators.,1Their analysis, published as ... , finds insufficient consistent data exist to recommend a ... sold under various trade names, such as Synthroid ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... that the U.S. Food and Drug Administration has approved ... prostate cancer patients, marks the beginning of an era ... the standard therapeutic arsenal against cancer, say Dana-Farber Cancer ... effectiveness in patients. The study the results ...
... ... Illness (NAMI), NAMIWalks help raise funds for local programs. , ... (PRWEB) -- May is Mental Health Month. This weekend, Saturday ... NAMIWalks to raise public awareness about facts concerning mental illness and the ...
... from all drugs used to prevent organ rejection, researchers ... type of drug treatment used to prevent organ rejection ... new study finds. , Kidney transplant patients are at ... use of immunosuppressive drugs to prevent organ rejection. In ...
... ... gastroenterologists from around the world to launch the first international “World IBD Day” dedicated ... conference (May 2 -5) in New Orleans. , ... New York, New York (Vocus) April 29, 2010 -- ...
... of ill people triggered greater response than pictures of gun-wielding ... a sick person may give your immune system a boost, ... sets of slides on two different days. The first set ... either a slideshow that showed photos of people with pox, ...
... This release is available in French . ... in Immunology and Cancer (IRIC) of the Universit de Montral ... ribonucleic acid (RNA) engineering laboratory in Canada. Led by Franois ... of Gerardo Ferbeyre, biochemistry researcher with the Faculty of Medicine ...
Cached Medicine News:Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 2Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 3Health News:NAMIWalks Kicks-off “Mental Health Month”; Fun Events that Support Serious Work 2Health News:Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 3Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 4Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 5Health News:Cells programmed to cure and even prevent cancer 2
... Streptavidin magnetic beads are designed ... biotinylated molecules such as DNA, ... cell lysates or hybridization reactions. ... dispersed, it can also be ...
... Streptavidin magnetic beads are ... covalently coupled to a ... substrates can be useful ... experiments including mRNA isolation ...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Medicine Products: